Other languages Iterum Therapeutics plc

Equities

ITRM

IE000TTOOBX0

Market Closed - Nasdaq Other stock markets 01:30:00 02/05/2024 am IST			5-day change	1st Jan Change
1.59 ^USD	+3.92%		+0.63%	-19.29%

29/04	Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem	CI
28/03	Transcript : Iterum Therapeutics plc, Q4 2023 Earnings Call, Mar 28, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem	29/04
Iterum Therapeutics plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28/03
Iterum Therapeutics Plans to Engage Financial Advisor to Evaluate Strategic Alternatives	06/03
Iterum Therapeutics plc Announces Positive Topline Results from Its Phase 3 Reassure Clinical Trial of Oral Sulopenem in Un Complicated Urinary Tract Infections	30/01
Iterum Therapeutics plc Announces the Resignation of Mark Chin as Director, Effective December 31, 2023	30/12
Iterum Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Iterum Therapeutics plc Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections	24/23/24
Iterum Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11
Iterum Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12
Iterum Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10
Iterum Therapeutics Reports Dosing First Patient in Late-Stage Urinary Tract Infections Trial	20/22/20
Iterum Announces First Patient Dosed in Reassure, A Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections	20/22/20
Iterum Therapeutics Files $100 Million Mixed-Securities Shelf	10/22/10
Iterum Therapeutics plc Announces Issuance of Allowance for A U.S. Patent Covering Oral Sulopenem	19/22/19
Iterum Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12
Sector Update: Health Care Stocks Edging Lower at Close	12/22/12
Sector Update: Health Care Stocks Still Little Changed	11/22/11
Iterum Therapeutics Lands Special Protocol Assessment Agreement with FDA; Shares Rise	11/22/11
Iterum Therapeutics plc Announces Special Protocol Assessment Agreement with the FDA	11/22/11
Iterum Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2022	13/22/13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Iterum Therapeutics plc

Equities

ITRM

IE000TTOOBX0

Other languages

Filters